Trends in nanobody radiotheranostics.

As the smallest antibody fragment with specific binding affinity, nanobody-based nuclear medicine has demonstrated significant potential to revolutionize the field of precision medicine, supported by burgeoning preclinical investigations and accumulating clinical evidence. However, the visualization...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 52; no. 6; pp. 2225 - 2239
Autores principales: Long, Xingru, Cheng, Sixuan, Lan, Xiaoli, Wei, Weijun, Jiang, Dawei
Formato: Journal Article
Publicado: Springer Nature May2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184671084&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 184671084
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: May2025
      vid: 52
      iid: 6
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        184671084
        182175440
        10.1007/s00259-025-07077-6
        184671084
      ppf: 2225
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Trends in nanobody radiotheranostics.
      aug:
        au:
          Long, Xingru
          Cheng, Sixuan
          Lan, Xiaoli
          Wei, Weijun
          Jiang, Dawei
        affil: https://ror.org/00p991c53 Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., 430022, Wuhan, Hubei, China
      sug:
      ab: As the smallest antibody fragment with specific binding affinity, nanobody-based nuclear medicine has demonstrated significant potential to revolutionize the field of precision medicine, supported by burgeoning preclinical investigations and accumulating clinical evidence. However, the visualization of nanobodies has also exposed their suboptimal biodistribution patterns, which has spurred collaborative efforts to refine their pharmacokinetic and pharmacodynamic profiles for improved therapeutic efficacy. In this review, we present clinical results that exemplify the benefits of nanobody-based molecular imaging in cancer diagnosis. Moreover, we emphasize the indispensable role of molecular imaging as a tool for evaluating and optimizing nanobodies, thereby expanding their therapeutic potential in cancer treatment in the foreseeable future.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N